A team at Children’s National Research and Innovation Campus is working on something new that could change the way we pinpoint pain, and how effectively we treat it. The technology could give hope to ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...

US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an ...

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

In a small clinical study, researchers in the US examined the nature of new-onset pain reported by people with long COVID and explored potential associations between long COVID symptoms and pain.

A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...